Recent vaccine effectiveness studies reveal a stark disparity in influenza protection across age groups. Adults aged 18-49 achieve 65% vaccine effectiveness, while those aged 50-64 see protection drop to 45%, and adults 65 and older experience only 25% effectiveness with standard vaccines. This substantial decline underscores why enhanced formulations are medically necessary.
The newly approved UK adjuvanted trivalent flu vaccine directly targets this protection gap by stimulating stronger immune responses in older adults. Evidence from the Centers for Disease Control and Prevention confirms that adjuvanted vaccines significantly improve effectiveness in populations over 65. This regulatory approval represents a data-driven solution to a well-established clinical challenge, potentially improving health outcomes for millions of older UK residents during annual flu seasons.
Was this article helpful?
